Peter, is this the report you are referring to?
Human amyloid-B synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Randall J Bateman 1-3, Ling Y Munsell 4, John C Morris 1,3,5, Robert Swarm 6, Kevin E Yarasheski 4, & David M Holtzman 1-3,7
Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-B (AB) in the brain and disease-causing mutations in precursor protein or in enzymes that produce AB indicate dysregulation of production or clearance of AB. Whether dysregulation of AB synthesis or clearance causes the most common form of Alzheimer disease (sporatic > 99% of cases), however, is not known. Here, we describe a method to determine the production and clearance of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of AB in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to access underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmicodynamic effects on proposed disease causing pathways.
Report...
neuro.wustl.edu |
